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Middle EastAbstract Objectives: The Saudi Project for Assessment of Coronary Events (SPACE) registry is
the ﬁrst in Saudi Arabia to study the clinical features, management, and in-hospital outcomes of
acute coronary syndrome (ACS) patients.
Methods: We conducted a prospective registry study in 17 hospitals in Saudi Arabia
between December 2005 and December 2007. ACS patients included those with ST-elevation
myocardial infarction (STEMI), non-ST elevation myocardial infarction and unstable angina; both
were reported collectively as NSTEACS (non-ST elevation acute coronary syndrome).
Results: 5055 patients were enrolled with mean age ± SD of 58 ± 12.9 years; 77.4% men,
82.4% Saudi nationals; 41.5% had STEMI, and 5.1% arrived at the hospital by ambulance. His-
tory of diabetes mellitus was present in 58.1%, hypertension in 55.3%, hyperlipidemia in 41.1%,
and 32.8% were current smokers; all these were more common in NSTEACS patients, except for
smoking (all P< 0.0001). In-hospital medications were: aspirin (97.7%), clopidogrel (83.7%),
beta-blockers (81.6%), angiotensin converting enzyme inhibitors/angiotensin receptor blockers
(75.1%), and statins (93.3%). Median time from symptom onset to hospital arrival for STEMI
patients was 150 min (IQR: 223), 17.5% had primary percutaneous coronary intervention
(PCI), 69.1% had thrombolytic therapy, and 14.8% received it at less than 30 min of hospital arri-
val. In-hospital outcomes included recurrent myocardial infarction (1.5%), recurrent ischemia
(12.6%), cardiogenic shock (4.3%), stroke (0.9%), major bleeding (1.3%). In-hospital mortality
was 3.0%.
Conclusion: ACS patients in Saudi Arabia present at a younger age, have much higher preva-
lence of diabetes mellitus, less access to ambulance use, delayed treatment by thrombolytic
therapy, and less primary PCI compared with patients in the developed countries. This is the ﬁrst
national ACS registry in our country and it demonstrated knowledge-care gaps that require fur-
ther improvements.
ª 2011 King Saud University. Production and hosting by Elsevier B.V. All rights reserved.1. Introduction
Ischemic heart disease represents a global health care burden,
and is expected to increase by more than 120% in developing
countries by the year 2020 (Lopez et al., 2006; Yusuf et al.,
2001a; Reddy, 2004; Yusuf et al., 2001b). This is related to
the high prevalence of cardiovascular risk factors, such as dia-
betes mellitus (DM), hypertension (HTN), smoking, and
hyperlipidemia; which likely resulted from signiﬁcant changes
in the lifestyle behaviors in the last few decades; such as re-
duced exercise and poor dietary habits. In addition, a knowl-
edge-care gap has been shown by several acute coronary
syndrome (ACS) registries, but scarce data are available in
the Arabian populations of the Middle Eastern region (Zubaid
et al., 2009). The Saudi Project for Assessment of Coronary
Events (SPACE) registry was initiated to study the clinical fea-
tures, management, and in-hospital outcomes of ACS patients
in the Kingdom of Saudi Arabia in comparison to other world-
wide ACS populations, in addition to potentially improve the
quality of care.2. Methods
The SPACE study is a prospective registry and a quality
improvement initiative of all consecutive ACS patients that
were admitted to the participating hospitals. Ethics committees
at each hospital approved the study. The diagnosis of the dif-
ferent types of ACS was based on the deﬁnitions of the Amer-
ican College of Cardiology key data elements and deﬁnitions
for measuring the clinical management and outcomes of pa-
tients with acute coronary syndromes (Cannon et al., 2001).
Serum cardiac biomarkers used to assist in the diagnosis of
myocardial injury were measured locally at each hospital’s lab-
oratory using its own assays and reference ranges.
2.1. Study design and population
The study included hospitalized patients with ST-segment ele-
vation myocardial infarction (STEMI), non ST-segment eleva-
tion myocardial infarction (NSTEMI), and unstable angina
(UA). The NSTEMI and UA patient groups were combined
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syndrome). The study extended from December 2005 until
December 2007. Patients had to be 18 years of age or older
and there were no exclusion criteria. The details of the pilot
study design were outlined previously (AlHabib et al., 2009).
2.2. Study organization
A Case Report Form (CRF) for each patient with suspected
ACS was ﬁlled out upon hospital admission by assigned phy-
sicians working in each hospital using standard deﬁnitions,
and completed throughout the patient’s hospital stay. All
CRFs were veriﬁed by a cardiologist then sent to the principal
coordinating center, where the forms were further checked for
incomplete data and mistakes before submission for ﬁnal anal-
ysis. To avoid double-counting patients, each patient’s
national identiﬁcation number was used. Thus, only the ﬁrst
ACS admission was included for each patient. Patients who
presented directly to the emergency department (ED) were
labeled as ‘‘own’’, while those who were transferred from a
non-registry hospital were labeled as ‘‘referral’’. An indepen-
dent clinical research organization (Dubai Pharmaceutical
Co., Dubai, UAE) was contracted to randomly audit all data
collected from 20% of the hospitals in phase-I. Data accuracy
was found to be more than 99%.
2.3. Case report form data variables
Data collected included the following variables: patient’s
demographics, past medical history, provisional diagnosis on
admission and ﬁnal discharge diagnosis, ECG ﬁndings, labora-
tory investigations, medical therapy, use of cardiac procedures
and interventions, in-hospital outcomes, and mortality. The
consistency of data collection was maintained using data col-
lection standards, ﬁeld deﬁnitions, and explanations at each
participating site. The following deﬁnitions were used; body
mass index (BMI): weight in kilograms divided by the square
meter of the height, DM: self-reported or being on oral hypo-
glycemic agents and/or insulin, HTN: self-reported, on anti-
hypertensive therapy, history of systolic blood pressure more
than 140 mmHg or diastolic blood pressure more than
90 mmHg, current smoking: cigarette, cigar, pipe, or shisha
smoking during the last 1 year of the index admission, hyper-
lipidemia: self-reported or being on treatment for hyperlipid-
emia, coronary artery disease (CAD): history of angina or
myocardial infarction (MI), family history of premature
CAD: history of angina, MI, or sudden cardiac death in
ﬁrst-degree relatives at age less than 55 years in men and less
than 65 years in women, recurrent MI: two or more out of
three criteria: new-onset chest pain or discomfort, new eleva-
tion in cardiac enzymes, and new ECG changes consistent with
ischemia or infarction, recurrent ischemia: new-onset chest
pain or discomfort with or without new ST-segment depression
and/or T-wave inversion on ECG but without elevation in car-
diac enzymes, congestive heart failure: shortness of breath on
exertion and/or at rest, paroxysmal nocturnal dyspnea, and/
or orthopnea associated with clinical signs of pulmonary
and/or peripheral edema requiring treatment with diuretic
therapy, cardiogenic shock: persistent hypotension (systolic
blood pressure of less than 90 mmHg) unresponsive to ﬂuid
administration and requirement for intravenous inotropic
therapy or insertion of intra-aortic balloon pump, stroke: clin-ical evidence of hemiparesis, hemiplegia, or impaired speech
with or without brain CT-scan or MRI conﬁrmation, major
bleeding: a drop in hemoglobin of greater than 5 g/dl
(0.5 g/l) or bleeding causing hemodynamic instability or
requiring blood transfusion.
2.4. Statistical analysis
Data were summarized as means ± SD if they were normally
distributed; otherwise, they were summarized as the median
and interquartile range (IQR). Differences between groups
were assessed using chi square or Fisher’s exact test for cate-
gorical variables, student t-test for continuous variables for
normally distributed variables, and the Mann–Whitney U test
for skewed variables. All analyses were considered signiﬁcant
at P< 0.05. The analysis was performed using SPSS soft-
ware, version 17. We excluded ‘‘referral’’ cases from other
non-registry hospitals in the analysis of ‘‘therapy-related tim-
elines’’ in STEMI and new or presumed new left bundle
branch block (LBBB) patients who underwent TT or primary
PCI because of insufﬁcient and/or inaccurate data, and also
those who presented to the hospital at more than 12 h of
symptom onset. We also excluded ‘‘referral’’ cases in the anal-
ysis of the ambulance use to get an accurate reporting of
mode of transportation of ACS patients from the community
to the hospitals.3. Results
3.1. Study population characteristics
Over a 24-month period, 5055 ACS patients were enrolled
from 17 hospitals in the Kingdom of Saudi Arabia. One third
of these hospitals was non-tertiary care hospitals and had no
cardiac catheterization or cardiac surgery facilities.
There were 2096 (41.5%) STEMI/new LBBB, and 2959
(58.5%) NSTEACS patients. The NSTEACS patients in-
cluded 1840 (62.2%) NSTEMI and 1119 (37.8%) UA patients.
Table 1 shows the baseline characteristics, CAD risk factors,
clinical features upon presentation, and key investigations
for the overall study population and its ACS sub-types. The
mean age ± SD of the overall population was 58 ± 12.9 years
and over three quarters were men. The prevalence of CAD
risk factors was high; three-ﬁfths had DM, over half had
HTN, one-third were current smokers, and two-ﬁfths had
hyperlipidemia. Median BMI ± SD was 27.6 ± 6.1 kg/m2.
Only 5.1% of ‘‘own’’ patients arrived at the hospital in an
ambulance (overall rate of own and referral was 20%), one-
ﬁfth had clinical evidence of congestive heart failure upon pre-
sentation, over three-ﬁfths had positive serum troponin, and
nearly two-thirds had coronary angiography. Compared with
STEMI patients, those with NSTEACS were older and more
likely to be Saudis, have a history of PCI, coronary artery by-
pass graft (CABG) surgery, DM, HTN, hyperlipidemia,
stroke, and were more likely to present with ischemic chest
pain and to undergo coronary angiogram during hospitaliza-
tion (P< 0.0001 for all comparisons). However, STEMI pa-
tients were more likely to be men, current smokers, to have
hypotension (systolic blood pressure 6 90 mmHg), and posi-
tive serum troponin upon clinical presentation (P< 0.0001
for all comparisons).
Table 1 Patients’ baseline characteristics and key investigations.
Variables Overall n= 5055
n (%)
STEMI/new LBBB




Mean age (SD), years 58 (12.9) 55.4 (13.1) 58.6 (12.9) <0.0001
Male sex, n (%) 3914 (77.4) 1767 (84.3) 2147 (72.4) <0.0001
Saudi nationality, n (%) 4164 (82.4) 1583 (75.5) 2581 (87.3) <0.0001
BMI, median (IQR) 27.6 (6.1) 27.4 (5.8) 28.1 (6.5) <0.001
Diabetes mellitus, n (%) 2937 (58.1) 1092 (52.1) 1845 (62.3) <0.0001
Hypertension, n (%) 2783 (55.3) 855 (40.9) 1928 (65.5) <0.0001
Current smoking, n (%) 1638 (32.4) 903 (43.1) 734 (24.8) <0.0001
Hyperlipidemia, n (%) 2084 (41.4) 559 (26.7) 1525 (51.9) <0.0001
History of CAD, n (%) 2145 (42.4) 469 (22.4) 1676 (56.6) <0.0001
History of PCI, n (%) 698 (13.8) 121 (5.7) 577 (19.4) <0.0001
History of CABG, n (%) 295 (5.8) 31 (1.4) 264 (8.9) <0.0001
History of CVA/TIA, n (%) 309 (6.1) 90 (4.3) 219 (7.4) <0.0001
Family history of premature CAD* 719 (15.4) 281 (14.3) 431 (16.2) 0.078
Killip class > 1, n (%) 940 (20.4) 344 (19.1) 596 (21.1) 0.02
SBP < 90 mmHg, n (%) 148 (3.2) 89 (4.9) 59 (2.1) <0.0001
HR> 100 beats per minute, n (%) 678 (14.8) 262 (14.5) 416 (15) 0.85
Ischemic chest pain, n (%) 3057 (87.6) 1730 (84.5) 1327 (92.2) <0.0001
Ambulance use**, n (%) 186 (5.1) 102 (8.3) 84 (3.5) 0.17
Positive serum troponin***, n (%) 3148 (62.5) 1424 (68.3) 1724 (58.2) <0.0001
Coronary angiogram, n (%) 3400 (67.2) 1327 (63.4) 2073 (69.9) <0.0001
NSTEACS = non-ST elevation acute coronary syndrome; STEMI = ST-elevation myocardial infarction; LBBB: left bundle branch block;
CAD= coronary artery disease; PCI = percutaneous coronary intervention; CABG= coronary artery bypass graft; CVA/TIA= cerebro-
vascular accident/transient ischemic attack; SBP = systolic blood pressure; HR= heart rate. *Family history of premature CAD was unknown
in 7% of the overall study cohort.
** Denominator is ‘‘own’’ patients only. The overall ambulance use (own and referral) was 20%.
*** Serum troponin was not done or unavailable in 17.8% of the overall study cohort.
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Fig. 1 shows the ﬂow sheet of the acute revascularization treat-
ments for STEMI/ new LBBB patients. Of 1232 STEMI/new
LBBB ‘‘own’’ patients, 905 (73.5%) presented at less than
12 h of symptom onset. Only 102 (8.3%) patients arrived at
the hospital in an ambulance, and the median time from symp-
tom onset to hospital arrival was 150 min (IQR: 223). 625
(69.1%) patients were treated with thrombolytic therapy
(TT), 93 (14.8%) received TT at less than 30 min of hospital
arrival, and the median door-to-needle time (DNT) was
52 min (IQR 55). The most commonly used TT was streptoki-
nase (46%), followed by retaplase (32.2%). 158 (17.5%)
patients had primary PCI. 114 (12.6%) patients did not receive
TT or primary PCI, and did not have a contraindication to
either strategy, i.e. reperfusion shortfall.
3.3. In-hospital medications, procedures, and outcomes
Table 2 shows the high use of in-hospital evidence-based med-
ications. Most of the patients received aspirin and statins, over
four-ﬁfths received clopidogrel and beta-blockers, and three-
quarters received angiotensin converting enzyme inhibitors
and/or angiotensin receptor blockers (ACE-I/ARBs). Over
one-third received glycoprotein IIb/IIIa inhibitors (GP IIb/
IIIa-I), over one-third had PCI, and 8.4% had CABG surgery.
The NSTEACS patients were more likely to receive clopido-
grel, beta-blockers, statins, GP IIb/IIIa-I, and undergo CABG
surgery, while STEMI patients were more likely to receive aspi-
rin, anticoagulants (unfractionated or low molecular weight
heparin), and undergo PCI (P< 0.05 for all comparisons).Table 3 shows the in-hospital mortality and outcomes. The
overall in-hospital mortality was low (154 patients, 3.0%). The
most frequent complications were recurrent ischemia (638
patients, 12.6%) and congestive heart failure (519 patients,
10.2%), whereas rates of stroke (48 patients, 0.9%) and major
bleeding (68 patients, 1.3%) were very low. STEMI patients
had higher in-hospital mortality and cardiovascular complica-
tions (P< 0.05 for all comparisons) but similar major bleed-
ing rates compared with NSTEACS patients. There was no
difference in outcomes between ‘‘own’’ and ‘‘referral’’ patients
(data not shown).
4. Discussion
SPACE is the ﬁrst registry for ACS patients in the Kingdom of
Saudi Arabia. It provides a good representation of the clinical
management of ACS patients, since several hospitals (second-
ary and tertiary) from all geographic regions of Saudi Arabia
and most health care providers were involved.
Our study showed that ACS patients in Saudi Arabia have
several unique features compared with their counterparts in
other populations. Nearly two-ﬁfths of our patients had STE-
MI compared with one-third in other ACS populations
reported worldwide (Goodman et al., 2009; Yan et al., 2007;
Mehta, 2006; Rosengren et al., 2006; Steg et al., 2002). This
is probably due to the relatively young average age of ACS
presentation (58 years), which is almost a decade younger than
those of developed countries. However, the rate of STEMI is
very similar to that of ACS patients from other Arabian Gulf
countries and Malaysia (Zubaid et al., 2009; Cannon et al.,
2001; Goodman et al., 2009; Yan et al., 2007; Mehta et al.,
Figure 1 Acute revascularization treatments for SPACE-own
STEMI/ new LBBB patients who presented to the hospital at less
than 12 h from symptom onset. *Eight patients had missing data
about revascularization therapies. **DNT: door-to-needle time.
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less than the 60.6% rate reported in India (Xavier et al., 2008).
This is likely because of the overall younger age of the popula-
tion in developing countries (The International Bank for
Reconstruction and Development/The World Bank: WorldTable 2 In-hospital treatments of the overall, STEMI/LBBB, and N
Variables Overall n= 5055 n (%) STEM I/new LBBB n=
Aspirin 4932 (97.7) 2057 (98.4)
Clopidogrel 4227 (83.7) 1676 (80.1)
Beta-blocker 4118 (81.6) 1625 (77.7)
ACE inhibitors/ARB 3801 (75.1) 1600 (76.4)
Statins 4707 (93.3) 1932 (92.4)
Anticoagulants 4178 (86.2) 1687 (85.2)
GPIIb/IIIa-I 1746 (34.5) 778 (37.1)
PCI 1775 (35.3) 888 (42.6)
CABG 424 (8.4) 105 (5.0)
NSTEACS = non-ST elevation acute coronary syndrome; STEMI = ST
PCI = percutanous coronary intervention; CABG= coronary artery by
and/or angiotensin receptor blocker; GP IIb/IIIa-I = Glycoprotein IIb/IDevelopment Report 2007), in addition to the extremely high
prevalence of uncontrolled CAD risk factors in the general
population (Al-Elq, 2009; Eledrisi et al., 2007), and particu-
larly supported by the staggeringly high prevalence of DM,
involving 58% of our patients. To our knowledge, this is the
highest-ever reported rate of DM in an ACS population, which
is double – and sometimes triple – the DM rate reported in
other registries (Zubaid et al., 2009; Goodman et al., 2009;
Yan et al., 2007; Mehta et al., 2006; Rosengren et al., 2006; Steg
et al., 2002; Chin et al., 2008; Xavier et al., 2008). The rate of
DM was 40% in ACS patients from other Arabian Gulf coun-
tries (Zubaid et al., 2009), which is lower than in our study; this
may be because of the higher ratio of ‘‘expatriates to nation-
als’’ living in some of these countries relative to those in Saudi
Arabia, who are usually younger and otherwise apparently
healthy manual workers. Plausible explanations for this high
rate of DM include lack of regular exercise and adopting the
‘‘western’’ diet (Yusuf et al., 2004). These changes in the Ara-
bian culture of Saudi Arabia are probably the result of oil
wealth-induced ‘‘obesogenic urbanization’’ that has occurred
at a particularly rapid pace over only few generations (Guy
et al., 2009).
Our STEMI patients took an average of 150 min before
presenting to the ED compared with 140–170 min in developed
countries (Steg et al., 2002; Hasdai et al., 2002; Mandelzweig et
al., 2006). The infrequent use of ambulance services (5.1% in
‘‘own’’ patients) is one of the major reasons for delayed pre-
sentations. Other factors include the underestimation of the
importance of symptoms, trafﬁc congestion in major cities,
and the absence of a universal health care system provider.
Moreover, only 14.8% of our STEMI patients received TT
within the standard 30 min, likely because they were awaiting
approval of administration of care by the cardiology service,
transfer of patients to intensive care units to receive care,
and lack of the immediate availability of such care in the ED
of many hospitals. Primary PCI was done only in 17.5% of pa-
tients, a rate much lower than in developed countries (Good-
man et al., 2009). In addition, the ‘‘reperfusion shortfall’’
rate was also high (12.6%) but less than the 33% reported in
international registries, and similar to other Arabian Gulf
countries (9.3%) (Zubaid et al., 2009; Steg et al., 2002; Al-Mal-
lah et al., 2010).
Similar to recent trends reported by other ACS registries
(Goodman et al., 2009; Amsterdam et al., 2009; Fox et al.,
2007) our study showed high use of guidelines-recommendedSTEACS patients.










-elevation myocardial infarction; LBBB: left bundle branch block;
pass graft. ACE-I/ARB= angiotensin converting enzyme inhibitor
IIa Inhibitors.
Table 3 In-hospital outcomes of the overall, STEMI/LBBB, and NSTEACS patients.
Variables Overall n= 5055
n (%)
STEM I/new LBBB




Death 154 (3.0) 94 (4.5) 60 (2.0) <0.0001
Recurrent myocardial infarction 77 (1.5) 49 (2.3) 28 (0.9) <0.0001
Recurrent ischemia 638 (12.6) 317 (15.1) 321 (10.8) <0.0001
Congestive heart failure 519 (10.2) 239 (11.4) 280 (9.4) 0.02
Cardiogenic shock 220 (4.3) 156 (7.4) 64 (2.1) <0.0001
Stroke 48 (0.9) 30 (1.4) 18 (0.6) <0.0001
Major bleeding 68 (1.3) 27 (1.2) 41 (1.3) NS
NSTEACS = non-ST elevation acute coronary syndrome; STEMI = ST-elevation myocardial infarction; LBBB: left bundle branch block; NS:
non-signiﬁcant.
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nary angiography, PCI, and GP IIb/IIIa-I are similar to those
in developed countries, but more than double the rates in
many other Middle Eastern and Asian countries (Goodman
et al., 2009; Yan et al., 2007; Mehta et al., 2006; Rosengren
et al., 2006; Steg et al., 2002; Chin et al., 2008; Xavier et al.,
2008; Amsterdam et al., 2009; Fox et al., 2007). These ﬁndings
reﬂect the wide availability of tertiary care hospitals in Saudi
Arabia that managed to establish high-caliber technical and
human resources in the past few decades. However, in our
study, it remains to be shown whether coronary revasculariza-
tion was done for those ACS patients with high-risk coronary
artery disease (Cohen et al., 2009).
The overall low in-hospital mortality of 3% is similar to
contemporary data from developed countries and some Ara-
bian Gulf countries, but lower than those reported in Yemen
and poor communities in India (Goodman et al., 2009; Yan
et al., 2007; Mehta et al., 2006; Rosengren et al., 2006; Steg et
al., 2002; Chin et al., 2008; Xavier et al., 2008; Amsterdam et
al., 2009). Low-socioeconomic strata correlate with poor access
to health care and high mortality (Xavier et al., 2008; Salomaa
et al., 2001; Alter et al., 1999). Improved overall socioeconomic
strata and high use of guidelines-based therapies in addition to
the relatively young age of ACS presentation are probably the
main reasons for the low mortality in our study. STEMI pa-
tients had higher in-hospital complications (except for major
bleeding) than those with NSTEACS. This is similar to other
ACS registries (Zubaid et al., 2009; Xavier et al., 2008) and is
most likely related to the longer times from symptom onset
to hospital arrival, and below-standard DNT.
Several limitations exist in our study. Firstly, as with most
other registries, hospital enrollment was voluntary; thus, the
study results may not be representative of clinical practice in
all hospitals in the country. In addition, hospitals that
participated in the registry might be more enthusiastic about
adherence to guidelines and quality improvement initiatives.
However, the wide geographic distribution of several hospitals
from different health care sectors in our study provides a rea-
sonable overall representation of ACS care. Secondly, there is
an inherent selection bias because of the observational nature
of the study design. Thirdly, the mortality rate might have
been underestimated because of missing major adverse events,
particularly ACS-related mortalities that happened prior to
admission to the cardiology service. We tried to mitigate this
issue by requiring all hospitals to enroll consecutive patients.
Fourthly, absence of accurate acute reperfusion treatmentsdata for STEMI patients in the ‘‘referral’’ hospitals might have
resulted in underestimation of the rate of use of such therapies.
Fifthly, serum troponin was not done routinely in all our pa-
tients, but the treating physicians believed that the ACS diag-
nosis was correct based on the clinical presentation, ECG
changes, and elevated serum CK-MB. Lastly, long-term out-
comes were unavailable.
In conclusion, SPACE is the ﬁrst ACS registry in Kingdom
of Saudi Arabia. It showed that our ACS patients present at a
relatively young age and have extremely high rates of DM.
STEMI- ‘‘own’’ patients rarely arrived to the hospital by an
ambulance, and only a few received either thrombolytic ther-
apy or primary PCI within the recommended time-line. Guide-
lines-based medications and coronary revascularization rates
were high, and in-hospital outcomes were low.Financial disclosure
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